The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials

2019 ◽  
Vol 111 ◽  
pp. 1-7 ◽  
Author(s):  
S. Cascinu ◽  
D. Poli ◽  
A. Zaniboni ◽  
S. Lonardi ◽  
R. Labianca ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Primary Tumour ◽  
Stage Ii ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Randomised Trials ◽  
Stage Iii Colon Cancer ◽  
Tumour Location

Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients

Medical Care ◽  
2009 ◽  
Vol 47 (12) ◽  
pp. 1229-1236 ◽  
Author(s):  
Amy J. Davidoff ◽  
Thomas Rapp ◽  
Ebere Onukwugha ◽  
Ilene H. Zuckerman ◽  
Nader Hanna ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Stage Iii ◽  
Stage Iii Colon Cancer

scholarly journals Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

2010 ◽  
Vol 2 (4) ◽  
pp. 261-272 ◽  
Author(s):  
Diogo Assed Bastos ◽  
Suilane Coelho Ribeiro ◽  
Daniela de Freitas ◽  
Paulo M. Hoff
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Combination Therapy ◽  
Current Practice ◽  
Stage Ii ◽  
Stage Iii ◽  
Future Prospects ◽  
Stage Iii Colon Cancer

scholarly journals Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions

2019 ◽  
Vol 26 (1) ◽  
Author(s):  
U. Bender ◽  
Y.S. Rho ◽  
I. Barrera ◽  
S. Aghajanyan ◽  
J. Acoba ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Risk Stratification ◽  
Disease Risk ◽  
Stage Ii ◽  
Stage Iii ◽  
Future Directions ◽  
Duration Of Therapy ◽  
Colon Cancer Risk ◽  
Genomic Assays

Background To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions.Methods PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer.Summary Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy.

scholarly journals Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

2017 ◽  
Vol 28 ◽  
pp. v168-v169
Author(s):  
S. Zunder ◽  
G. van Pelt ◽  
H. Gelderblom ◽  
R. Tollenaar ◽  
C. Mancao ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Stage Ii ◽  
Stage Iii ◽  
Tumour Stroma ◽  
Stage Iii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document